Xuanzhu Biopharm-B (02575.HK): New indication for piroxiciclib included in the 2026 National Basic Medical Insurance Drug Catalog

Zhitong Finance APP News, Xuanzhu Biopharma-B (02575.HK) announced that the new indication for its independently developed innovative drug Pyrotinib Tablets, in combination with an aromatase inhibitor (AI) for the first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer patients, has been included in the "National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug Catalog (2026)." The 2026 National Basic Medical Insurance Drug Catalog will officially take effect on January 1, 2027. As of the date of this announcement, all three indications approved in mainland China for Pyrotinib have been included in the National Basic Medical Insurance Drug Catalog.